HPR supports your R&D activities through:
Development and characterization of your NHP disease models
Preclinical evaluation of potential therapeutic candidates intended for clinical testing
AAALAC International standards for animal care
Hiroyuki Takamatsu, Ph.D., CEO
"Our clients are extremely satisfied with our contract studies, which were completed successfully by our technicians who are highly skilled in handling of nonhuman primates as well as rodents. In addition to our osteoarthritis, pain, and stroke models, HPR recently developed the photochemically-induced thrombosis (PIT) method to induce vascular cyclic flow reduction, a phenomenon observed in vascular thrombosis and cerebral ischemia. HPR integrated PIT with in vivo imaging technologies, including MRI and PET, to track disease progression in the same subject over time. We are fully committed to supporting your drug discovery efforts with professionalism and our extensive experiences and skill sets."
Ikuo Hayashi, Ph.D., COO
Founding of Hamamatsu Pharma Research, Inc in Japan
Main office / Central Research Facility established
Primate Center established
Accreditation by AAALAC International
Hamamatsu Pharma Research U.S.A., Inc. established
All studies are reviewed and approved by the Hamamatsu Pharma Research Animal Care and Use Committee.
Animal care and housing in accordance with the "Guide for Care ad Use of Laboratory Animals" (National Research Council, 2011)
Our primate center and central research facility are located in Japan and we hold cynomolous macaques.
8 holding rooms (up to 300 macaques)
4 procedure rooms
Central Research Facility
6 holding rooms
10 procedure rooms